GlobeNewswire Inc.··Proqr Therapeutics N.V.ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027
ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline